Publikationen

Publikationen der Medizinischen Klinik I 2014

Kommentare oder Korrespondenzen

1. Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O (2014) Commentary: vitamin D deficiency and liver cancer - cause, effect or myth? Authors' reply. ALIMENT PHARM THER, 39 (12): 1429-30

2. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H (2014) Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. ALIMENT PHARM THER, 39 (11): 1342-4

Originalarbeiten

1. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. NEW ENGL J MED, 370 (20): 1889-98

2. Akoglu B, Lafferton B, Kalb S, Yosuf SE, Herrmann E, Zeuzem S, Goßmann J, Kachel HG, Scheuermann EH, Faust D (2014) Rejection quantity in kidney transplant recipients is associated with increasing intracellular interleukin-2 in CD8+ T-cells. TRANSPL IMMUNOL, 31 (1): 17-21

3. Albert JG, Finkelmeier F, Friedrich-Rust M, Kronenberger B, Trojan J, Zeuzem S, Sarrazin C (2014) Identifying Indications for Percutaneous (PTC) vs. Endoscopic Ultrasound (EUS)- Guided "Rendezvous" Procedure in Biliary Obstruction and Incomplete Endoscopic Retrograde Cholangiography (ERC). Z GASTROENTEROL, 52 (10): 1157- 1163

4. Alao JP1, Sjölander JJ, Baar J, Özbaki-Yagan N, Kakoschky B, Sunnerhagen P. Caffeine stabilizes Cdc25 independently of Rad3 in Schizosaccharomyces pombe contributing to checkpoint override. Mol Microbiol. 2014 May;92(4):777-96

5. Albert JG, Lucas K, Filmann N, Herrmann E, Schröder O, Sarrazin C, Trojan J, Kronenberger B, Bojunga J, Zeuzem S, Friedrich-Rust M (2014) A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial. ENDOSCOPY, 46 (10): 857-61

6. Albert JG, Tal A, Bechstein WO, Trojan J, Schnitzbauer A (2014) Three late adverse events of choledochoduodenostomy of which the endoscopist should be aware: direct retrograde cholangioscopy is helpful for diagnosis and therapy. GASTROINTEST ENDOSC, -: -

7. Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, Bludzin W, Jinga M, Ulusoy S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zeuzem S, the AI, European Longitudinal Chronic Hepatitis B Study Group (2014) Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. ANTIVIR THER, -: -

8. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JGP, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HLA, for the VIRGIL Surveillance Study Group (2014) Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. GUT, -: -

9. Badenhoop K (2014) Genetics: Vitamin D and type 2 diabetes mellitus-hype or hope? NAT REV ENDOCRINOL, -: -

10. Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauss TF, Dong Z, Gustafson KR, Biondi RM, Henrich CJ, 
McMahon JB, Colburn NH, Schmid T, Brüne B (2014) Characterization of pomiferin triacetate as a novel mTOR and 
translation inhibitor. BIOCHEM PHARMACOL, 88 (3): 313-21

11. Bergis D, Bergis PM, Hermanns N, Zink K, Haak T (2014) Coronary artery disease as an independent predictor of 
survival in patients with type 2 diabetes and Charcot neuro-osteoarthropathy. ACTA DIABETOL, 51 (6): 1041-8

12. Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon- Domanec I, DeMasi R, Picchio G, Luo D, De Meyer S, Zeuzem S (2014) Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. LIVER 
INT, -: -

13. Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J (2014) Current practice in the diagnosis and 
management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J CROHNS 
COLITIS, 8 (10): 1308-14

14. Blumenstein I, Shastri YM, Stein J (2014) Gastroenteric tube feeding: techniques, problems and solutions. WORLD J 
GASTROENTERO, 20 (26): 8505-24

15. Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GLH, Friedrich-Rust M, Fraquelli M, 
Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P, from the ARDENT group and/or AFEF (2014) An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J HEPATOL, -: -

16. Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HLA (2014) Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. ALIMENT PHARM THER, 40 (7): 811-8

17. Bruggmann P, Berg T, Øvrehus ALH, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HSM, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz MLG, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KDE, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ (2014) Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat, 21 Suppl 1: 5-33

18. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS, Hezode C, Rizzetto M, Parana R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J (2014) Telaprevir Twice Daily is Noninferior to Telaprevir Every 8 hrs for Patients with Chronic Hepatitis C. GASTROENTEROLOGY, 146 ((3)): 744-753

19. Canbay A, Feldstein A, Kronenberger B, Schulze-Osthoff K, Bantel H (2014) [Cytokeratin 18 as marker for non- invasive diagnosis and prognosis of acute and chronic liver diseases]. Z GASTROENTEROL, 52 (3): 290-5

20. Cloherty G, Cohen D, Sarrazin C, Wedemeyer H, Chevaliez S, Herman C, Bernstein B, Pawlotsky JM (2014) HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. ANTIVIR THER, -: -

21. Dawoodji A, Chen JL, Shepherd D, Dalin F, Tarlton A, Alimohammadi M, Penna-Martinez M, Meyer G, Mitchell AL, 
Gan EH, Bratland E, Bensing S, Husebye ES, Pearce SH, Badenhoop K, Kämpe O, Cerundolo V (2014) High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients. J IMMUNOL, 193 (5): 2118-26

22. de Boer YS, van Gerven NMF, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JPH, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MMJ, Vrolijk JM, Kraal G, Mulder CJJ, van Nieuwkerk CMJ, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G, Dutch Autoimmune Hepatitis Study Group, LifeLines Cohort Study, Study of Health in Pomerania (2014) Genome- wide association study identifies variants associated with autoimmune hepatitis type 1. GASTROENTEROLOGY, 147 (2): 443-52.e5

23. Doller A, Badawi A, Schmid T, Brauß T, Pleli T, Zu Heringdorf DM, Piiper A, Pfeilschifter J, Eberhardt W (2014) The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. EXP CELL RES, -: -

24. Döring G, Bragonzi A, Paroni M, Aktürk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, Kohlhäufl M, Wagner TOF, Loebinger MR, Bilton D, Tunney MM, Elborn JS, Pier GB, Konstan MW, Ulrich M (2014) BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J CYST FIBROS, 13 ((2)): 156-63

25. Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Behrendt P, Brown RJP, Ciesek S, Wedemeyer H, Sarrazin C, Kaderali L, Pietschmann T, Steinmann E (2014) Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. HEPATOLOGY, 60 (2): 508-20

26. Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O (2014) Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat, -: -

27. Everson G, Cooper C, Hézode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Andreone P, Bruno S, Ferenci P, Zeuzem S, Brunda M, Le Pogam S, Nájera I, Zhou J, Navarro MT, Voulgari A, Shulman NS, Yetzer ES (2014) DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. LIVER INT, -: -

28. Farnik H, Ferreirós N, Labocha S, Geisslinger G, Zeuzem S, Sarrazin C, Vermehren J (2014) Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. SCAND J GASTROENTERO, 49 (12): 1473-9

29. Farnik H, Weigt J, Malfertheiner P, Grützmann A, Gossner L, Friedrich-Rust M, Zeuzem S, Sarrazin C, Albert JG (2014) A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography. ENDOSCOPY, 46 (1): 16-21

30. Farnik H, Zimmermann T, Herrmann E, Bechstein WO, Kronenberger B, Galle PR, Labocha S, Ferreiros N, Geisslinger G, Zeuzem S, Sarrazin C, Welker MW (2014) Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. LIVER INT, -: -

31. Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Picchio G, Sarrazin C (2014) HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy. ANTIVIR THER, -: -

32. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fdl, Moum B, Vavricka SR, Schröder O, Herrmann E, Blumenstein I (2014) Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. INFLAMM BOWEL DIS, 20 (5): 936-45

33. Finkelmeier F, Bettinger D, Köberle V, Schultheiß M, Zeuzem S, Kronenberger B, Piiper A, Waidmann O (2014) Single measurement of hemoglobin predicts outcome of HCC patients. MED ONCOL, 31 (1): 806

34. Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O (2014) Severe 25- hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. ALIMENT PHARM THER, 39 (10): 1204-12

35. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M (2014) Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. GASTROENTEROLOGY, 146 (7): 1669-79.e3

36. Friedrich-Rust M, Welte M, Welte C, Albert J, Meckbach Y, Herrmann E, Kannengiesser M, Trojan J, Filmann N, Schroeter H, Zeuzem S, Bojunga J (2014) Capnographic monitoring of propofol-based sedation during colonoscopy. ENDOSCOPY, 46 (3): 236-44

37. Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Zhou J, Yetzer ES, Ballester R, Dwyer C, Tong X, Nájera I, Bertasso A, Hammond J, Kindrick A, Morcos PN, Smith P, Stancic S, Shulman NS (2014) Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. LIVER INT, -: -

38. Gnirß K, Fiedler M, Krämer-Kühl A, Bolduan S, Mittler E, Becker S, Schindler M, Pöhlmann S (2014) Analysis of determinants in filovirus glycoproteins required for tetherin antagonism. VIRUSES-BASEL, 6 (4): 1654-71

39. Grammatikos G, Ferreiros N, Bon D, Schwalm S, Dietz J, Berkowski C, Fitting D, Herrmann E, Zeuzem S, Sarrazin C, Pfeilschifter J (2014) Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in HCV but not HBV infection. HEPATOLOGY, -: -

40. Grammatikos G, Jabara CB, Ahmad MQ, Herrmann E, Zeuzem S, Welsch C (2014) Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients. ANTIVIR THER, 19 (5): 455-61

41. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg T, Sarrazin C (2014) Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One, 9 (2): e87974

42. Grammatikos G, Mühle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J, Zeuzem S, Sarrazin C, Pfeilschifter J (2014) Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. BBA-BIOENERGETICS, -: -

43. Grammatikos G, Farnik H, Bon D, Böhlig A, Bader T, Berg T, Zeuzem S, Herrmann E (2014) The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. J Viral Hepat, 21 (8): 533-41

44. Gruber-Rouh T, Naguib NNN, Eichler K, Ackermann H, Zangos S, Trojan J, Beeres M, Harth M, Schulz B, Nour-Eldin A NE, Vogl TJ (2014) Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer, 134 (5): 1225-31

45. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H, HIDIT-1 Study Group (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. HEPATOLOGY, 60 (1): 87-97

46. Hézode C, Brainard D, Pol S, Libert O, Symondq W, McHutchison J, Zeuzem S (2014) [In Process Citation]. MED MALADIES INFECT, 44 (6 Suppl): 1

47. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind- Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S (2014) Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. GUT, -: -

48. Hinrichsen I, Ernst BP, Nuber F, Passmann S, Schäfer D, Steinke V, Friedrichs N, Plotz G, Zeuzem S, Brieger A (2014) Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1. Mol Cancer, 13: 11

49. Hinrichsen I, Kemp M, Peveling-Oberhag J, Passmann S, Plotz G, Zeuzem S, Brieger A (2014) Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. PLoS One, 9 (1): e84453

50. Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, Falorni A, Gan EH, Hulting AL, Kasperlik-Zaluska A, Kämpe O, Løvås K, Meyer G, Pearce SH (2014) Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J INTERN MED, 275 ((2)): 104-15

51. Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Gines P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V, CANONIC Study Investigators EASL-CLIF Consortium (2014) The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute- on-chronic liver failure. J HEPATOL, -: -

52. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V, CANONIC study investigators of the EASL-CLIF Consortium (2014) Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J HEPATOL, 61 (5): 1038-47

53. Kaiser T, Zeuzem S, Lichtinghagen R, Welker MW, Geilenkeuser WJ, Kruse R, Neumaier M, Thiery J, Schmidt M (2014) Multi-center proficiency tests for Lab-MELD score diagnostics to improve the quality and safety for patients awaiting liver transplantation. CLIN CHEM LAB MED, 52 (12): e287-9

54. Kasama Y, Mizukami T, Kusunoki H, Peveling-Oberhag J, Nishito Y, Ozawa M, Kohara M, Mizuochi T, Tsukiyama- Kohara K (2014) B-cell-intrinsic hepatitis C virus expression leads to B-cell-lymphomagenesis and induction of NF-κB signalling. PLoS One, 9 (3): e91373

55. Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK (2014) Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis. J HEPATOL, -: -

56. König AB, Junginger S, Reusch J, Louwen F, Badenhoop K (2014) Gestational Diabetes Outcome in a Single Center Study: Higher BMI in Children After Six Months. HORM METAB RES, 46 (11): 804-9

57. Kubitz R, Dröge C, Kluge S, Stross C, Walter N, Keitel V, Häussinger D, Stindt J (2014) Autoimmune BSEP Disease: Disease Recurrence After Liver Transplantation for Progressive Familial Intrahepatic Cholestasis. CLIN REV ALLERG IMMU, -: -

58. Lange CM, Bellecave P, Dao Thi VL, Tran HTL, Penin F, Moradpour D, Gouttenoire J (2014) Determinants for membrane association of the hepatitis C virus NS2 protease domain. J VIROL, 88 (11): 6519-23

59. Lange CM, Gouttenoire J, Duong FHT, Morikawa K, Heim MH, Moradpour D (2014) Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-α. J IMMUNOL, 192 (12): 6037-44

60. Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP, The AI463-121 European Longitudinal Chronic Hepatitis B Study Group (2014) Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat, -: -

61. Leung NWY, Herrmann E, Lau GKK, Chan HLY, So TMK, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV (2014) Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther, -: -

62. Lynen Jansen P, Kopp I, Nothacker M, Zeuzem S (2014) [In Process Citation]. Z GASTROENTEROL, 52 (10): 1151-2

63. Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HLA, de Knegt RJ, Veldt BJ (2014) Effect of thrombocytopenia on treatment tolerability and 
outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J HEPATOL, 61 (3): 482-91

64. Maasoumy B, Hunyady B, Calvaruso V, Makara M, Vermehren J, Haragh A, Susser S, Bremer B, Cloherty G, Manns MP, Craxì A, Wedemeyer H, Sarrazin C (2014) Performance of Two HCV RNA Assays during Protease Inhibitor- 
Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS One, 9 (11): e110857

65. Manns MP, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk- Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M (2014) Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from 
Phase IIb and III studies. J Viral Hepat, -: -

66. Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, 
Morais E, Bjork S, Lescrauwaet B, Kamar D, Simon K, the AI, Longitudinal Study Group (2014) Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study. ANTIVIR THER, -: -

67. Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Mani Subramanian G, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Jenny Heathcote E (2014) Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J HEPATOL, -: -

68. Markova AA, Mihm U, Schlaphoff V, Lunemann S, Filmann N, Bremer B, Berg T, Sarrazin C, Zeuzem S, Manns MP, Cornberg M, Herrmann E, Wedemeyer H (2014) PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic Hepatitis C. PLoS One, 9 (4): e94512

69. Mauf S, Penna-Martinez M, Jentzsch T, Ackermann H, Henrich D, Radeke HH, Brück P, Badenhoop K, Ramos-Lopez E (2014) Immunomodulatory effects of 25-hydroxyvitamin D3 on monocytic cell differentiation and influence of vitamin D3 polymorphisms in type 1 diabetes. J STEROID BIOCHEM, 147C: 17-23

70. Meyer G, Neumann K, Badenhoop K, Linder R (2014) Increasing prevalence of Addison's disease in German females: Health insurance data 2008-2012. EUR J ENDOCRINOL, 170 ((3)): 367-73

71. Mihm U, Welker MW, Teuber G, Wedemeyer H, Berg T, Sarrazin C, Böhm S, Alshuth U, Herrmann E, Zeuzem S (2014) Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection. J Viral Hepat, 21 (1): 42-52

72. Mitchell AL, Macarthur KDR, Gan EH, Baggott LE, Wolff ASB, Skinningsrud B, Platt H, Short A, Lobell A, Kämpe O, Bensing S, Betterle C, Kasperlik-Zaluska A, Zurawek M, Fichna M, Kockum I, Nordling Eriksson G, Ekwall O, Wahlberg J, Dahlqvist P, Hulting AL, Penna-Martinez M, Meyer G, Kahles H, Badenhoop K, Hahner S, Quinkler M, Falorni A, Phipps-Green A, Merriman TR, Ollier W, Cordell HJ, Undlien D, Czarnocka B, Husebye E, Pearce SHS (2014) Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European cohorts. PLoS One, 9 (3): e88991

73. Morikawa K, Gouttenoire J, Hernandez C, Thi VLD, Tran HTL, Lange CM, Dill MT, Heim MH, Donzé O, Penin F, Quadroni M, Moradpour D (2014) Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. HEPATOLOGY, 59 ((2)): 423-33

74. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S, EMERGE study group (2014) A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J HEPATOL, -: -

75. Nitschke K, Barriga A, Schmidt J, Timm J, Viazov S, Kuntzen T, Kim AY, Lauer GM, Allen TM, Gaudieri S, Rauch A, Lange CM, Sarrazin C, Eiermann T, Sidney J, Sette A, Thimme R, López D, Neumann-Haefelin C (2014) HLA-B(∗)27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. J HEPATOL, 60 ((1)): 22-9

75. Oertel BG, Vermehren J, Huynh TT, Doehring A, Ferreiros N, Zimmermann M, Geisslinger G, Lötsch J (2014) Cytochrome p450 epoxygenase dependence of opioid analgesia: fluconazole does not interfere with remifentanil- mediated analgesia in human subjects. CLIN PHARMACOL THER, 96 (6): 684-93

76. Peiffer KH, Akhras S, Himmelsbach K, Hassemer M, Finkernagel M, Carra G, Nuebling M, Chudy M, Niekamp H, Glebe D, Sarrazin C, Zeuzem S, Hildt E (2014) Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. J HEPATOL, -: -

78. Peiffer KH, Niemeyer M, Buslau A, Kohnen T, Muckenthaler MU, Zeuzem S, Sarrazin C (2014) Iron deficiency anaemia and cataracts in a patient with haemochromatosis. GUT, 63 ((4)): 686

79. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M (2014) Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. DIGEST LIVER DIS, 46 (10): 923-7

80. Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C (2014) Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. J CLIN VIROL, 59 (3): 148-55

81. Pleli T, Martin D, Kronenberger B, Brunner F, Köberle V, Grammatikos G, Farnik H, Martinez Y, Finkelmeier F, Labocha S, Ferreirós N, Zeuzem S, Piiper A, Waidmann O (2014) Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study. PLoS One, 9 (7): e103532

82. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B (2014) ABT-450/r- ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. NEW ENGL J MED, 370 (21): 1973-82

83. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HSM, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz MLG, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KDE, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus ALH, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat, 21 Suppl 1: 34-59

84. Rosenberger I, Schmithals C, Vandooren J, Bianchessi S, Milani P, Locatelli E, Israel LL, Hübner F, Matteoli M, Lellouche JP, Franchini MC, Passoni L, Scanziani E, Opdenakker G, Piiper A, Kreuter J (2014) Physico-chemical and toxicological characterization of iron-containing albumin nanoparticles as platforms for medical imaging. J CONTROL RELEASE, 194C: 130-137

85. Scheuing N, Badenhoop K, Borkenstein M, Konrad K, Lilienthal E, Laubner K, Naeke A, Rami-Merhar B, Thon A, Wiemann D, Holl RW, for the German/Austrian Diabetes Prospective Documentation Initiative (2014) Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes? PEDIATR DIABETES, -: -

86. Scheuing N, Berger G, Bergis D, Gohlke B, Konrad K, Laubner K, Lilienthal E, Moser C, Schütz-Fuhrmann I, Thon A, Holl RW, on behalf of the German/Austrian Diabetes Prospective Documentation (DPV) Initiative (2014) Adherence to clinical care guidelines for cystic fibrosis-related diabetes in 659 German/Austrian patients. J CYST FIBROS, 13 (6): 730-736

87. Scheuing N, Holl RW, Dockter G, Hermann JM, Junge S, Koerner-Rettberg C, Naehrlich L, Smaczny C, Staab D, Thalhammer G, van Koningsbruggen-Rietschel S, Ballmann M (2014) High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study. PLoS One, 9 (11): e112578

88. Schneider MD, Sarrazin C (2014) Antiviral therapy of hepatitis C in 2014: do we need resistance testing? ANTIVIR RES, 105: 64-71

89. Schulze B, Bergis D, Balermpas P, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C (2014) Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncol Lett, 7 (2): 534-540

90. Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L (2014) Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC INFECT DIS, 14: 465

91. Seguí N, Navarro M, Pineda M, Köger N, Bellido F, González S, Campos O, Iglesias S, Valdés-Mas R, López-Doriga A, Gut M, Blanco I, Lázaro C, Capellá G, Puente XS, Plotz G, Valle L (2014) Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype. GUT, -: -

92. Sekyere SO, Suneetha PV, Kraft A, Zhang S, Dietz J, Sarrazin C, Manns MP, Schlaphoff V, Cornberg M, Wedemeyer H (2014) A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J HEPATOL, -: -

93. Sterneck M, Settmacher U, Ganten T, Sarrazin C, Speidel N, Broering D, Heyne N, Paulus E, Mertens M, Fischer L (2014) Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients. TRANSPL P, 46 (1): 234- 40

94. Strobel F, Reusch J, Penna-Martinez M, Ramos-Lopez E, Klahold E, Klepzig C, Wehrle J, Kahles H, Badenhoop K (2014) Effect of a Randomised Controlled Vitamin D Trial on Insulin Resistance and Glucose Metabolism in Patients with Type 2 Diabetes Mellitus. HORM METAB RES, 46 ((1)): 54-8.

95. Susser S, Herrmann E, Lange C, Hamdi N, Müller T, Berg T, Perner D, Zeuzem S, Sarrazin C (2014) Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One, 9 (11): e112592

96. Tal AO, Filmann N, Makhlin K, Hausmann J, Friedrich-Rust M, Herrmann E, Zeuzem S, Albert JG (2014) The capsule endoscopy "suspected blood indicator" (SBI) for detection of active small bowel bleeding: no active bleeding in case of negative SBI. SCAND J GASTROENTERO, -: 1-5

97. Tal AO, Vermehren J, Friedrich-Rust M, Bojunga J, Sarrazin C, Zeuzem S, Trojan J, Albert JG (2014) Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc, 6 (1): 13-9

98. Trojan J, Vogl TJ, Zeuzem S, Albert JG (2014) A fractured duodenal self-expanding metal stent in a patient with pancreatic cancer. ENDOSCOPY, 46 (S 01): E386-E387

99. van der Meer AJ, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HLA (2014) Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. GUT, -: -

100. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HLA (2014) Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA-J AM MED ASSOC, 312 (18): 1927-8

101. van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HLA (2014) Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J HEPATOL, 60 (1): 191-6

102. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HLA (2014) The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J Viral Hepat, -: -

103. van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez- Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HLA, Reesink HW (2014) Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. ANTIVIR RES, 111C: 53-59

104. Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C (2014) Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J HEPATOL, 60 (5): 913-9

105. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S (2014) Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J HEPATOL, 61 (2): 200-9

106. Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F, Lotz G, Ferrucci P (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. ROFO-FORTSCHR RONTG, 186 (10): 937-44

107. Waidmann O, Kronenberger B, Scheiermann P, Köberle V, Mühl H, Piiper A (2014) Interleukin 22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma. HEPATOLOGY, 59 ((3)): 1207

108. Watcharin W, Schmithals C, Pleli T, Köberle V, Korkusuz H, Huebner F, Zeuzem S, Korf HW, Vogl TJ, Rittmeyer C, Terfort A, Piiper A, Gelperina S, Kreuter J (2014) Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging. EUR J PHARM BIOPHARM, -: -

109. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HSM, Cornberg M, Cramp ME, Dore GJ, Doss W, El- Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz MLG, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KDE, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus ALH, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E (2014) Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat, 21 Suppl 1: 60-89

110. Welsch C (2014) Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. Drug Discov Today Technol, 11: 19-25

111. Welsch C, Haselow K, Gouttenoire J, Schneider M, Morikawa K, Martinez Y, Susser S, Sarrazin C, Zeuzem S, Antes I, Moradpour D, Lange CM (2014) Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β- induction by efficient MAVS cleavage. J HEPATOL, -: -

112. Welzel TM, Zeuzem S (2014) Interferon-free strategies without a nucleoside/nucleotide analogue. SEMIN LIVER DIS, 34 (1): 47-57

113. Wiegand J, Wedemeyer H, Franke A, Rößler S, Zeuzem S, Teuber G, Wächtler M, Römmele U, Ruf B, Spengler U, Trautwein C, Bock CT, Fiedler GM, Thiery J, Manns MP, Brosteanu O, Tillmann HL, the German Hep-Net Acute Hepatitis B (GAHB) Study Group (2014) Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat, -: -

114. Wiesmann F, Naeth G, Sarrazin C, Berger A, Kaiser R, Ehret R, Knechten H, Braun P (2014) Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol, -: -

115. Witting V, Bergis D, Sadet D, Badenhoop K (2014) Thyroid disease in insulin-treated patients with type 2 diabetes: a retrospective study. Thyroid Res, 7 (1): 2

116. Wojzischke J, Flerchinger C, Marienfeld S, Bojunga J (2014) [Malnutrition in the hospital. Identifying risk patients]. PFLEGE Z, 67 (3): 166-9

117. Wong MSK, Leisegang MS, Kruse C, Vogel J, Schürmann C, Dehne N, Weigert A, Herrmann E, Brüne B, Shah AM, Steinhilber D, Offermanns S, Carmeliet G, Badenhoop K, Schröder K, Brandes RP (2014) Vitamin D promotes vascular regeneration. CIRCULATION, 130 (12): 976-86

118. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H, HIDIT-2 Study Group (2014) Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One, 9 (7): e101002

119. Yamane D, McGivern DR, Wauthier E, Yi M, Madden VJ, Welsch C, Antes I, Wen Y, Chugh PE, McGee CE, Widman DG, Misumi I, Bandyopadhyay S, Kim S, Shimakami T, Oikawa T, Whitmire JK, Heise MT, Dittmer DP, Kao CC, Pitson SM, Merrill AH, Reid LM, Lemon SM (2014) Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. NAT MED, 20 (8): 927-35

120. Yasuo S, Fischer C, Bojunga J, Iigo M, Korf HW (2014) 2-Arachidonoyl glycerol sensitizes the pars distalis and enhances forskolin-stimulated prolactin secretion in Syrian hamsters. CHRONOBIOL INT, 31 ((3)): 337-42

121. Yi M, Hu F, Joyce M, Saxena V, Welsch C, Chavez D, Guerra B, Yamane D, Veselenak R, Pyles R, Walker CM, Tyrrell L, Bourne N, Lanford RE, Lemon SM (2014) Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J VIROL, 88 (7): 3678-94

122. Younossi ZM, Stepanova M, Zeuzem S, Dusheiko G, Esteban R, Hezode C, Reesink HW, Weiland O, Nader F, Hunt SL (2014) Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J HEPATOL, 61 (2): 228-34

123. Zeuzem S (2014) Decade in review-HCV: Hepatitis C therapy-a fast and competitive race. NAT REV GASTRO HEPAT, 11 (11): 644-5

124. Zeuzem S (2014) [Prof. Dr. med. Peter Galle]. Z GASTROENTEROL, 52 (8): 799-800
125. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M (2014) Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. GASTROENTEROLOGY, 146 ((2)): 430-41

125. Zeuzem S, Dufour JF, Buti M, Soriano V, Buynak RJ, Mantry P, Taunk J, Stern JO, Vinisko R, Gallivan JP, Böcher W, Mensa FJ, the SOUND-C3 study group (2014) Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. LIVER INT, -: -

126. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subr